Using CRISPR-Cas9 for Therapeutic Protein Production (Review Article)
DOI:
https://doi.org/10.24203/ajpnms.v9i1.6115Keywords:
CRISPR/Cas9, genome editing, gene therapy, sgRNAAbstract
Existence of CRISPR/Cas9 systems in bacteria and archaea has been noted to be the reason for these organisms’ ability to disarm invading nucleic acids. Such immunity is noted to arise from the targeting of the invading nucleic acids by guiding RNAs (sgRNAs), their cleavage by Cas9 (an endonuclease), and their subsequent integration into CRISPR locus. Recent studies have shown that the CRISPR/Cas9 tool can be adopted for gene editing in eukaryotic cells and thus offering potential for its use to treat genetic conditions. In this review, CRISPR/Cas9 has been shown to be an effective genome-editing tool with studies showing efficacy in zygote editing, in-vivo editing of somatic cells and ex-vivo editing of somatic cells. Occurrence of off-target effects however make zygote editing in human cells ethically questionable due to possibility of introducing unwanted mutations that may be passed on to the progeny. Nevertheless, observations that such off-target effects arise mainly from the promiscuity of sgRNAs rather that errors in CRISPR/Cas9 system show promise for increased specificity by developing better sgRNAs. Such increased specificity will facilitate the adoption of CRISPR/Cas9 for clinical use in treatment of conditions such as β-thalassemia, cystic fibrosis, Duchenne muscular dystrophy and HIV.
References
Genome editing for all. (2014). Nature Biotechnology, 32(4), 295. doi:10.1038/nbt.2879
Lee, J. S., Grav, L. M., Lewis, N. E., & Kildegaard, H. F. (2015). CRISPR/ Cas9-mediated genome engineering of CHO cell factories: Applications and perspectives. Biotechnology Journal, 10(7), 979-94. doi:10.1002/biot.201500080032
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 337, 816-821. doi:10.1126/science.1225829
Savić, N., & Schwank, G. (2016). Advances in the therapeutic CRISPR/Cas9 genome editing. Translational Research, 168(), 15-21. http://dx.doi.org/10.1016/j.trsl.2015.09.008
Lanphier, E., & Urnov, F. (2015). Don’t edit the human germ line. Nature, 519, 410-411. Retrieved from http://www.nature.com/polopoly_fs/1.17111!/menu/main/topColumns/topLeftColumn/pdf/519410a.pdf
Reardon, S. (2015). Gene-editing wave hits clinic. Nature, 527, 146-147. Retrieved from http://www.nature.com/polopoly_fs/1.18737!/menu/main/topColumns/topLeftColumn/pdf/nature.2015.18737.pdf
Callaway, E. (2016). Embryo editing gets green light. Nature, 530, 18. Retrieved from http://www.nature.com/polopoly_fs/1.19270!/menu/main/topColumns/topLeftColumn/pdf/nature.2016.19270.pdf
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013). One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell, 153(4), 910-918. doi:10.1016/j.cell.2013.04.025.
Wu, Y., Liang, D., Wang, Y., Bai, M., Tang, W., Bao, S., … Li, J. (2013). Correction of a genetic disease in muse via use of CRISPR-Cas9. Cell Stem Cell, 13(6), 659-662. http://dx.doi.org/10.1016/j.stem.2013.10.016
Cyranoski, D. (2015). Embryo editing divides scientists. Nature, 519, 272. Retrieved from http://www.nature.com/polopoly_fs/1.17131!/menu/main/topColumns/topLeftColumn/pdf/519272a.pdf
Liang, P., Xu, Y., Zhang, X., Ding, C.,Huang, R., Zhang, Z., … Huang, J. (2015). CRISPR/Cas9-mediated gene editing in human triponuclear zygotes. Protein Cell, 6(5), 363-372. doi:10.1007/s13238-015-0153-5
Yin, H., Xue, W., Chen, S., Bogorad, R., Benedetti, E., Grompe, M., Koteliansky, V., … Anderson, D. G. (2014). Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nature Biotechnology, 32(6), 551-3. doi:10.1038/nbt.2884
Nelson, D. L., & Cox, M. M. (2004). Lehninger principles of biochemistry (4th ed.). New York: W. H. Freeman & Company
Ding, Q., Strong, A., Patel, K. M., Ng, S-L., Gosis, B. S., Regan, S. N., … Musunuru, K. (2014). Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circulation Research, 115(5), 488-492, doi:10.1161/CIRCRESAHA.115.304351
Lin, S. R., Yang, H. C., Kuo, Y. T., Liu, C. J., Yang, T. Y., Sung, K. C., … Chen, P. J. (2014). Molecular Therapy. Nucleic Acids, 19(3), e186. doi:10.1038/mtna.2014.38.
Xie, F., Ye, L., Chang, J. C., Beyer, A. I., Wang, J., … Kan, Y. W. (2014). Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Research, 24(9), 1526-33, doi:10.1101/gr.173427.114.
Schwank, G., Koo, B. K., Sasselli, V., Dekkers, J. F., Heo, I., Demircan, T., Clevers, H. (2013). Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell, 13(6), 653-8. doi:10.1016/j.stem.2013.11.002.
Li, H. L., Fujimoto, N., Sasakawa, N., Shirai, S., Ohkame, T., Sakuma, T., … Hotta, A. (2015). Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports, 4(1):143-54. doi: 10.1016/j.stemcr.2014.10.013.
Ousterout, D. G., Kabadi, A. M., Thakore, P. I., Majoros, W. H., Reddy, T. E., & Gersbach, C. A. (2015). Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nature Communications, 6, 6244. doi: 10.1038/ncomms7244
O’Green, H., Yu, A. S., & Segal, D. J. (2015). How specific is CRISPR/Cas9 really? Current Opinion in Chemical Biology, 29, 72-78. http://dx.doi.org/10.1016/j.cbpa.2015.10.001
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Ashraf Ullah Khan, Zabi Ullah
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
- Papers must be submitted on the understanding that they have not been published elsewhere (except in the form of an abstract or as part of a published lecture, review, or thesis) and are not currently under consideration by another journal published by any other publisher.
- It is also the authors responsibility to ensure that the articles emanating from a particular source are submitted with the necessary approval.
- The authors warrant that the paper is original and that he/she is the author of the paper, except for material that is clearly identified as to its original source, with permission notices from the copyright owners where required.
- The authors ensure that all the references carefully and they are accurate in the text as well as in the list of references (and vice versa).
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Attribution-NonCommercial 4.0 International that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- The journal/publisher is not responsible for subsequent uses of the work. It is the author's responsibility to bring an infringement action if so desired by the author.
